Organ Mapping Antibody Panels: a community resource for standardized multiplexed tissue imaging
- PMID: 37468619
- PMCID: PMC10406602
- DOI: 10.1038/s41592-023-01846-7
Organ Mapping Antibody Panels: a community resource for standardized multiplexed tissue imaging
Abstract
Multiplexed antibody-based imaging enables the detailed characterization of molecular and cellular organization in tissues. Advances in the field now allow high-parameter data collection (>60 targets); however, considerable expertise and capital are needed to construct the antibody panels employed by these methods. Organ mapping antibody panels are community-validated resources that save time and money, increase reproducibility, accelerate discovery and support the construction of a Human Reference Atlas.
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
A.E.W. is an employee and shareholder of Abcam PLC. J.F. is an employee of Cell Signaling Technology, Inc. J.C. is an employee and stakeholder of BioLegend. A.J.L. is an employee and shareholder of Thermo Fisher Scientific. E.M., L.L., C.S. and F.G. are employees of GE Research. B.R.S. is an inventor on patents and patent applications involving small molecule drug discovery, and the 3F3-FMA antibody, cofounded and serves as a consultant to Exarta Therapeutics and ProJenX Inc.; holds equity in Sonata Therapeutics, receives sponsored research from Sumitomo Pharma Oncology Inc and serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer and Feld LLP. M.P.S. is cofounder and advisory board member of Personalis, Qbio, January AI, Mirvie, Filtricine, Fodsel, Lollo and Protos. G.P.N. has equity in and is a scientific advisory board member of Akoya Biosciences, Inc. I.S.V. consults for Guidepoint Global, Cowen, Mosaic and NextRNA. N.G. is a cofounder and equity owner of Datavisyn. W.M. is an employee of Miltenyi Biotec B.V. and Co. KG. E.L. serves as a consultant for 10x Genomics, Moleculent AB, Pixelgen Technologies and Nautilus Biotechnology. K.G.D. is an employee of Akoya Biosciences. The remaining authors declare no competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
- UH3 CA246635/CA/NCI NIH HHS/United States
- UH3 CA256962/CA/NCI NIH HHS/United States
- U54 DK134302/DK/NIDDK NIH HHS/United States
- R35 CA209896/CA/NCI NIH HHS/United States
- R01 AG078803/AG/NIA NIH HHS/United States
- OT2 OD026671/OD/NIH HHS/United States
- U54 HG010426/HG/NHGRI NIH HHS/United States
- U54 AG075932/AG/NIA NIH HHS/United States
- T32 ES007028/ES/NIEHS NIH HHS/United States
- P30 DK020593/DK/NIDDK NIH HHS/United States
- T32 CA196585/CA/NCI NIH HHS/United States
- U24 CA268108/CA/NCI NIH HHS/United States
- U01 DK120447/DK/NIDDK NIH HHS/United States
- U01 HL148861/HL/NHLBI NIH HHS/United States
- OT2 OD026675/OD/NIH HHS/United States
- UG3 HL145600/HL/NHLBI NIH HHS/United States
- OT2 OD033759/OD/NIH HHS/United States
- P41 GM108569/GM/NIGMS NIH HHS/United States
- U54 AR081775/AR/NIAMS NIH HHS/United States
- UG3 CA268105/CA/NCI NIH HHS/United States
- U54 HL145608/HL/NHLBI NIH HHS/United States
- F32 DK128887/DK/NIDDK NIH HHS/United States
- U54 EY032442/EY/NEI NIH HHS/United States
- UG3 CA256962/CA/NCI NIH HHS/United States
- OT2 OD033758/OD/NIH HHS/United States
- UH3 CA246594/CA/NCI NIH HHS/United States
- U01 DK133766/DK/NIDDK NIH HHS/United States
